ISRCTN14473912已完成不适用
ow dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomised double-blind placebo controlled trial
eiden University Medical Center (LUMC) (The Netherlands)0 个研究点目标入组 200 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients treated at the Leiden anticoagulation clinic with an indication for long-term oral anticoagulant therapy using the vitamin K antagonist phenprocoumon
- •2. Age between 18 and 80 years
- •3. Informed consent
排除标准
- •1. Treatment by a medical specialist for liver failure
- •2. Haemo or peritoneal dialysis
- •3. Pregnancy or a planned pregnancy, puerperium
- •4. Any chronic condition with an expected median survival of less than 6 months
- •an expected interruption of oral anticoagulant treatment of more than 1 week
- •5. Self-management of oral anticoagulant therapy
- •6. Other drugs affecting haemostasis (aspirin, heparin, clopidogrel)
研究者
相似试验
已完成
不适用
ow dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomized double-blind placebo controlled trial.NL-OMON25820Trombosestichting Nederland200
已完成
不适用
Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosisCystic fibrosisISRCTN14200211Barts and the London NHS Trust (UK)40
已完成
2 期
the effect of vitamin K supplementation on bone factors in hemodialysis patientsIRCT20221217056845N1Gorgan University of Medical Sciences72
进行中（未招募）
1 期
To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis - Vitamin K supplementation in Cystic FibrosisCystic FibrosisEUCTR2006-000945-20-GBBarts and the London NHS Trust40
已完成
不适用
Evaluation of the Clinical use of vitamin K supplementation in post-menopausal women with OsteopeniaOsteopenia/osteoporosisMusculoskeletal DiseasesISRCTN61708241niversity Health Network, Toronto (Canada)440